

The Future of CGT Manufacturing: Expert Call w/ Ori Biotech

APRIL 16, 2024 | 10:00AM ET

Stephens is hosting a conference call for institutional investors with Jason Foster, the CEO of Ori Biotech, a proprietary, bespoke, and flexible manufacturing platform. This call will discuss the current state of the cell and gene therapy (CGT) industry and the role automated manufacturing solutions play within the industry including Ori's platform. In addition, we will discuss the future outlook for the CGT industry including key factors to enable the future growth and accessibility of these therapies.

About Jason Foster

Jason Foster is CEO and Executive Director of Ori Biotech, a cell and gene therapy manufacturing technology start-up. Ori's platform technology has the potential to enable the production of cell and gene therapies at market scale, for market relevant cost, making it possible for patients to get access to high quality, affordable cell therapies earlier in the treatment pathway. Mr. Foster has held leading roles building consulting, pharma and technology companies over the last 20 years.

Conference call date and time subject to change. To join the call or to obtain more information, please contact your Stephens sales representative.

Topics of Discussion:

- The automated cell therapy manufacturing ecosystem and opportunities for next generation technologies.
- Ori's technology platform and value proposition for CGT developers.
- The outlook for the CGT industry and opportunities to lower the COGS for these therapies.
- The state of the CGT end-market and the key factors to enable the future growth and accessibility of these therapies.

Conference Call Host

Jacob Johnson, CFA
Managing Director
Life Science Tools and Pharma
Services
(615) 279-4355
Jacob.Johnson@stephens.com

Stephens

INSTITUTIONAL EQUITIES & RESEARCH

stephens.com

f in  800-643-9691

© 2024 STEPHENS INC. MEMBER NYSE, SIPC | 111 CENTER STREET, LITTLE ROCK, AR 72201

[UNSUBSCRIBE](#) [EMAIL PREFERENCES](#) [VIEW ONLINE](#)

This announcement has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets or developments referred to in the material. The research analyst principally responsible for preparation of this announcement has received compensation that is based on the firm's overall revenue which includes investment banking revenue. To access current disclosures for the companies in this announcement, clients should refer to <https://stephens2.bluematrix.com/sellside/Disclosures.action> or contact your Stephens Inc. representative for additional information. Please also note that the announcement may include one or more links to external or third-party websites. Stephens Inc. has not independently verified the information contained on such websites and can provide no assurance as to the reliability of such information, and there can be no assurance that any opinions expressed on such websites reflect the opinions of Stephens Inc. or its management. Additional information available upon request.